Chronic transfusion and primary treatment of iron overload

0

Deferasirox FCT allows greater convenience and may be associated with fewer gastrointestinal side effects versus the original formulation. Dose adjustment increments, determined by titration monitoring, are lower for the FCT because of greater bioavailability” Tinsley and Hoehner-Cooper et al (2018).

Abstract:

Iron overload is a concern for patients who require chronic transfusions as a result of inherited or acquired anemias, including sickle cell disease, thalassemia, and myelodysplastic syndromes. Iron chelation therapy (ICT) is the primary treatment for iron overload in these patients. The ICT deferasirox, which has been available as an oral dispersible tablet for liquid suspension, is now also available as a once-daily, film-coated tablet (FCT). Deferasirox FCT allows greater convenience and may be associated with fewer gastrointestinal side effects versus the original formulation. Dose adjustment increments, determined by titration monitoring, are lower for the FCT because of greater bioavailability.



Reference:

Tinsley, S.M. and Hoehner-Cooper, C.M. (2018) Transitioning Patients With Iron Overload From Exjade to Jadenu. Journal of Infusion Nursing. 41(3), p.171–175.

doi: 10.1097/NAN.0000000000000278.

Share.

Comments are closed.